Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;101(3):194-201.
doi: 10.1016/j.jdermsci.2021.01.004. Epub 2021 Jan 22.

Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma

Nozomi Jimura  1 , Kazuyasu Fujii  2 , Zhiwei Qiao  3 , Ryuto Tsuchiya  3 , Yuki Yoshimatsu  3 , Tadashi Kondo  4 , Takuro Kanekura  5
Affiliations

Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma

Nozomi Jimura et al. J Dermatol Sci. 2021 Mar.

Abstract

Background: Histone deacetylase inhibitors (HDACi) are used to treat patients with cutaneous T-cell lymphoma (CTCL), but they show limited efficacy. Hence, combination therapies should be explored to enhance the effectiveness of HDACis.

Objective: This study was conducted to identify novel therapeutic targets that can be combined with HDACis for treating CTCL.

Methods: We performed a global kinome profiling assay of three CTCL cell lines (HH, MJ, and Hut78) with three HDACis (romidepsin, vorinostat, and belinostat) using the PamChip® microarray. The three cell lines were co-treated with romidepsin and an inhibitor against the tyrosine kinase pathway.

Results: Principal component analysis revealed that kinome expression patterns were mainly related to the cell origin and were not affected by the drugs. Few kinases were commonly activated by the HDACis. Most identified kinases were Src-associated molecules, such as annexin A2, embryonal Fyn-associated substrate, and progesterone receptor. Phosphorylated Src was not observed in any untreated cell lines, whereas Src phosphorylation was detected in two of the three cell lines after HDACi treatment. Ponatinib, a Src inhibitor, significantly enhanced romidepsin-induced apoptosis not only in HH, MJ, and Hut78 cells, but also in Myla and SeAx CTCL cell lines.

Conclusion: The Src pathway is a possible target for combination therapy involving HDACis for CTCL.

Keywords: Cutaneous T-cell lymphoma; Histone deacetylase inhibitor; Kinome; Src pathway; Tyrosine kinase.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

MeSH terms